{"prompt": "['2.2.1.3 Ongoing Clinical Trials', 'Avelumab is currently in clinical development in 12 phase III trials.', 'As of 05 November 2015, 1353 subjects have received at least 1 dose of Avelumab at doses ranging', 'from 1.0 to 20 mg/kg in Trial EMR 100070-001. Overall, 1300 subjects have received the proposed', 'dose of 10 mg/kg in the pooled expansion cohort. No new safety signals were identified upon', 'preliminary review of data from these subjects.', 'The safety profile of avelumab has so far been evaluated from data in more than 1400 subjects in 4', 'ongoing trials in subjects with various solid tumors: Trial EMR 100070-001, Japan local Trial EMR', '100070-002, Trial EMR 100070-003, and Trial EMR 100070-004 These safety data from subjects', 'with different tumor types treated with avelumab suggest an acceptable safety profile of the', 'compound. Most of the observed events were either in line with those expected in subjects with', 'advanced solid tumors or with similar class effects of MoAb blocking the PD-1/PD-L1 axis.', 'Infusion-related reactions including drug hypersensitivity reactions and immune-mediated adverse', 'reactions have been identified as important risks for avelumab. Respective risk mitigation measures', 'have been implemented in all ongoing clinical studies with Avelumab.', '2.3 Information on Other Trial-Related Therapy', '2.3.1 Cyclophosphamide', 'Cyclophosphamide, a nitrogen mustard, is an alkylating agent from the oxazophosphorine group.', 'The former undergoes spontaneous degradation whereas the latter is excreted into the urine. These', 'compounds crosslink DNA by adding an alkyl group (CnH2n+1) to the guanine base of DNA, at the', 'number seven nitrogen atom of the imidazole ring. This induces inhibition of DNA replication,', 'leading to cell death. In addition, CYC adds methyl or other alkyl groups onto molecules where', 'they do not belong which in turn inhibits their correct utilization by base pairing and causes a', 'miscoding of DNA. Alkylating agents are cell cycle-nonspecific. CYC damages DNA via the', 'formation of cross-links (bonds between atoms in the DNA which prevents DNA from being', 'separated for synthesis or transcription, and via the induction of mispairing of the nucleotides', 'leading to mutations. CYC exerts its cytotoxic effect on both resting and dividing lymphocytes. It', 'undergoes extensive metabolism via the cytochrome-P450 enzymatic system with phosphoramide', 'mustard and acrolein as the main active and inactive metabolites, respectively.12', '2.3.1.1 Metronomic Cyclophosphamide', 'CONFRONT Study v. 1.1 del 07/05/2018 - Study Protocol', '10']['Cyclophosphamide was used at dosages far below the maximum tolerated doses (MTD) against', 'many tumor types in a scheduling called \"metronomic\".', 'Metronomic chemotherapy refers to the administration of cytotoxic drugs at doses significantly less', 'than the MTD and with short or no drug-free breaks. When metronomic cyclophosphamide', '(mCTX) is given, a daily scheduling and the oral route of administration are usually preferred.', 'Penel N et al recently reviewed this topic18.', 'Most dosages of oral mCTX vary between daily 50 mg to 100 mg total dose or per square meter of', 'body surface.', 'mCTX was also combined with other drugs including chemotherapy, anti-angiogenetic drugs and', 'monoclonal antibodies directed against the PD-1 - PD-L1 axis.', 'Mechanism of action and toxicity of mCTX', 'Initially, the mechanism of action of mCTX was believed to depend on its antiangiogenic activity', 'demonstrated in experimental models. More recently, additional effects of mCTX were identified', 'both in experimental models and in humans. They include the selective elimination of', 'immunosuppressive cells and the stimulation of the antitumor immune responses. Hao Y-B et al', 'have recently reviewed this topic19.', 'mCTX showed activity against a numebr of different solid tumors, including some who do not', '20', 'respond to standard dose of cyclophosphamide, such as prostate cancer, colon cancer and sarcoma\"', 'In the next paragraphs we describe the toxicity profile of mCTX at different scheduling and dosages', 'given either alone or in combination with other drugs, including immune checkpoints inhibitors, in', 'retrospective and prospective clinical studies.', 'Metronomic cyclophosphamide: Doses, schedulings and toxicity', 'Cyclophosphamide 50 mg daily without drug-free break', 'In 2010, Nelius t et al reported a pilot prospective study with cylophosphamide, 50mg daily given', 'to 17 patients with metastatic prostate cancer all pre-treated with docetaxel. No grade III or IV', 'toxicity was recorded and no one patient required treatment breaks due to side effects. Less than', '13% of the patients experienced grade I-II toxicity21.', 'Ladoire S et al reported a second prospectic study in 23 prostate cancer pts with cyclophosphamide', '50mg daily. All these patients were symptomatic, 3 had ECOG performance status of 3 and 13', 'were ECOG 2. Median age was 74 (range 55 - 88).', 'All patients were preatreated with docetaxel, and 13 received 2 ore more lines of chemotherapy', 'before cyclophosphamide. One patient with extensive bone metastases and heavy pre-treatment,', 'CONFRONT Study v. 1.1 del 07/05/2018 - Study Protocol', '11']\n\n###\n\n", "completion": "END"}